menu
    • menu
    [{"orgOrder":0,"company":"Adalvo","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Fentanyl","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Adalvo \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Adalvo"},{"orgOrder":0,"company":"Adalvo","sponsor":"Formosa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Steroid","year":"2025","type":"Licensing Agreement","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Adalvo \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Adalvo"},{"orgOrder":0,"company":"Adalvo","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Antibiotic","year":"2023","type":"Licensing Agreement","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Adalvo \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Adalvo"},{"orgOrder":0,"company":"Adalvo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"MALTA","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifamycin Sodium","moa":"DNA-directed RNA polymerase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Adalvo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Inapplicable"},{"orgOrder":0,"company":"Adalvo","sponsor":"CNX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Partnership","leadProduct":"Nitrofurantoin","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Adalvo \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Adalvo"},{"orgOrder":0,"company":"Adalvo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"MALTA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Voltage-gated calcium channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Adalvo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Inapplicable"},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"MALTA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Adalvo \/ AmbioPharm","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ AmbioPharm"},{"orgOrder":0,"company":"Adalvo","sponsor":"Pfenex","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"MALTA","productType":"Peptide","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Adalvo \/ Pfenex","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Pfenex"},{"orgOrder":0,"company":"Adalvo","sponsor":"Adamed Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"MALTA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2","graph1":"Urology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet, Modified Release","sponsorNew":"Adalvo \/ Adamed Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Adamed Pharma"},{"orgOrder":0,"company":"Adalvo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"MALTA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adalvo \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Inapplicable"},{"orgOrder":0,"company":"Adalvo","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"MALTA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adalvo \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ Sandoz B2B"},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"MALTA","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adalvo \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"Adalvo \/ AmbioPharm"},{"orgOrder":0,"company":"Adalvo","sponsor":"Zentiva","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"MALTA","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Adalvo \/ Zentiva","highestDevelopmentStatusID":"1","companyTruncated":"Adalvo \/ Zentiva"}]

    Find Clinical Drug Pipeline Developments & Deals by Adalvo

    Menu

    Adalvo

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Recipient : Formosa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Formosa and Adalvo Announce Licensing Deal for Clobetasol Ophthalmic Suspension

                            Details : Adalvo gains exclusive rights to the commercialization of APP13007 (clobetasol propionate), for post-operative inflammation and pain following ocular surgery in the European and Brazilian markets.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            May 28, 2025

                            Lead Product(s) : Clobetasol Propionate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Recipient : Formosa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrofurantoin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : CNX Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            CNX and Adalvo Sign Deal for Nitrofurantoin PR Commercialization

                            Details : Through the partnership, Nitrofurantoin PR-Generic (nitrofurantoin), will be available in the UK as the first generic version. It is indicated for the treatment of acute uncomplicated UTIs.

                            Product Name : Nitrofurantoin PR-Generic

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            December 16, 2024

                            Lead Product(s) : Nitrofurantoin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : CNX Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen

                            Details : Victoza-Generic (liraglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is indicated for the treatment of patients with type 2 diabetes mellitus.

                            Product Name : Victoza-Generic

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            June 13, 2024

                            Lead Product(s) : Liraglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifamycin Sodium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adalvo Addresses Traveller’s Diarrehea with Rifamycin SV MMX

                            Details : Rifamycin SV MMX (rifamycin sodium) is a DNA-directed RNA polymerase inhibitor antibiotic, indicated for the treatement of Travelers’ Diarrhea.

                            Product Name : Rifamycin SV MMX

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            May 10, 2024

                            Lead Product(s) : Rifamycin Sodium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pregabalin

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adalvo Announces Successful DCP Approval of Pregabalin Prolonged Release Tablets

                            Details : Pregabalin Prolonged Release Tablets is a unique formulation helps in increasing patient's adherence, it is the backbone medication indicated in the treatment of Neuropathic pain.

                            Product Name : Lyrica CR-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 22, 2023

                            Lead Product(s) : Pregabalin

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifamycin Sodium

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Recipient : Cosmo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cosmo & Adalvo Sign Supply Deal for Rifamycin SV MMX® 200MG Across Key Global Regions

                            Details : Under the licensing agreement, Adalvo will receive from Cosmo the exclusive right to develop and commercialize Rifamycin SV MMX (rifamycin sodium) for the treatement of Travelers’ Diarrhea.

                            Product Name : Rifamycin SV MMX

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            September 04, 2023

                            Lead Product(s) : Rifamycin Sodium

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Recipient : Cosmo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Undisclosed

                            Sponsor : Zentiva

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            Zentiva Extends Its Collaboration with Adalvo and Strengthens Its Offering in Respiratory, CNS and Dermatology

                            Details : Under the terms of collaboration, Zentiva will complement their product offering with the support of longstanding partners Adalvo with new molecules in a variety of therapeutical areas like Respiratory, CNS and Dermatology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 01, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Zentiva

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solifenacin Succinate,Tamsulosin

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Sponsor : Adamed Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adalvo and Adamed Pharma Team up to Launch Solifenacin + Tamsulosin in Europe

                            Details : Solifenacin Succinate is a muscarinic receptor antagonist and tamsulosin is an alpha-1A and alpha-1B adrenergic receptor antagonist used in combination to treat benign prostatic hyperplasia.

                            Product Name : Vesomni-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 23, 2023

                            Lead Product(s) : Solifenacin Succinate,Tamsulosin

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Sponsor : Adamed Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Sandoz B2B

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sandoz To Exclusively Commercialize Six Products In The Us, Reinforcing Global Leadership Position In Off-pate...

                            Details : Under the agreement, Sandoz will get the rights to commercialize six products in the US across key therapeutic areas, including antifungal/antibiotic, oncology and pulmonary.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Sandoz B2B

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed

                            Adalvo

                            Malta arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Adalvo Acquires Its First Branded Product, Onsolis

                            Details : Adalvo will be the sole and exclusive owner of the Onsolis® (fentanyl) and will obtain full rights on the product, taking over all existing business and all market authorizations, globally, including the US.

                            Product Name : Onsolis

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            February 08, 2022

                            Lead Product(s) : Fentanyl

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth